YNYoshimitsu Nakanishi

Yoshimitsu Nakanishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshimitsu Nakanishi has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epitope-diverse autoantibodies induce neutrophil–epithelial niches driving kidney injury in ANCA-associated glomerulonephritis

    by Masayuki Nishide, Hiroaki Matsushita, Yumiko Mizuno, Kei Nishimura, Patrick M. Lelliott, Shoji Kawada, Takashi Fujii, Shogo Kamikawaji, Tatsuya Nonaka, Daisuke Motooka, et al.

    Autoantibody-mediated inflammation drives tissue injury in autoimmune diseases, yet how pathogenic antibodies evoke local immune activation remains poorly understood. Here, we show that spatially organized neutrophil–epithelial niches contribute to kidney injury in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody–associated glomerulonephritis. Single-cell–resolved spatial transcriptomics of treatment-naïve patient kidney biopsies identified early-phase inflammatory niches enriched with HAVCR1+ injured proximal tubular epithelial cells, neutrophils, lymphocytes, and TREM2+ macrophages. Injured epithelial cells expressed chemokines including CXCL6 and CXCL16, defining a microenvironment associated with local immune cell accumulation. Neutrophils within these niches were characterized by transcriptional programs enriched for type II interferon and Fcγ receptor (FcγR)-related signaling. Mechanistically, combinations of monoclonal anti-MPO antibodies recognizing distinct epitopes enhanced neutrophil activation and induced pauci-immune crescentic glomerulonephritis in mice, recapitulating key aspects of epithelial injury observed in human kidneys. One-armed anti-MPO antibodies engineered to minimize FcγR engagement ameliorated kidney injury in mice. Together, these findings identify pathogenic neutrophil–epithelial niche formation as a driver of autoimmune kidney injury.


  • Endothelial semaphorin 6D controls immune responses under cold stress through regulation of sympathetic innervation

    by Yumiko Mizuno, Hiroaki Matsushita, Yoko Fukushima, Shuhei Kobuchi, Shohei Koyama, Masayuki Nishide, Yoshimitsu Nakanishi, Mayuko Izumi, Maiko Naito, Kazuichi Maruyama, et al.

    Environmental temperature significantly influences immune responses. Cold exposure suppresses host defense against infections and exacerbates autoimmune and allergic conditions. However, the molecular mechanisms underlying temperature-dependent immune regulation remain unclear. In this study, we evaluated the cold-activated sympathetic modulation of immune responses. We presented that semaphorin 6D (Sema6D), an axon guidance molecule, is required for proper sympathetic nerve distribution. While both wild-type and Sema6d-/- mice developed experimental autoimmune encephalomyelitis (EAE) similarly at room temperature (22 °C), disease progression was attenuated in Sema6d-/- mice specifically under cold exposure (10 °C). Additionally, endothelial cell–specific Sema6d-/- (Sema6dΔVEcad) mice exhibited cold-specific attenuation of EAE development. Notably, Sema6dΔVEcad mice showed increased perivascular sympathetic innervation in lymph nodes, which resulted in enhanced norepinephrine-induced tissue hypoxia and cellular stress responses, leading to attenuated T-cell responses under cold exposure. These immunosuppressive effects were restored by pharmacological ablation of the sympathetic nerves, showing that the proper sympathetic nerve distribution in lymphoid organs is critical for immune competence under cold exposure. Collectively, these findings not only indicate that Sema6D is a key axon guidance molecule for sympathetic nerve distribution but also show a potential mechanism underlying the environmentally modulated progression of autoimmune diseases.


  • Open Access

    Sema6D forward signaling impairs T cell activation and proliferation in head and neck cancer

    by Takashi Hirai, Yujiro Naito, Shohei Koyama, Yoshimitsu Nakanishi, Kentaro Masuhiro, Mayuko Izumi, Tomoki Kuge, Maiko Naito, Yumiko Mizuno, Yuta Yamaguchi, et al.

    Immune checkpoint inhibitors (ICIs) are indicated for a diverse range of cancer types, and characterizing the tumor immune microenvironment is critical for optimizing therapeutic strategies, including ICIs. T cell infiltration and activation status in the tumor microenvironment greatly affects the efficacy of ICIs. Here, we show that semaphorin 6D (Sema6D) forward signaling, which is reportedly involved in coordinating the orientation of cell development and migration as a guidance factor, impaired the infiltration and activation of tumor-specific CD8 + T cells in murine oral tumors. Sema6D expressed by nonhematopoietic cells was responsible for this phenotype. Plexin-A4, a receptor for Sema6D, inhibited T cell infiltration and partially suppressed CD8 + T cell activation and proliferation induced by Sema6D stimulation. Moreover, mouse oral tumors, which are resistant to PD-1–blocking treatment in wild-type mice, showed a response to the treatment in Sema6d -KO mice. Finally, analyses of public data sets of human head and neck squamous cell carcinoma, pan-cancer cohorts, and a retrospective cohort study showed that SEMA6D was mainly expressed by nonhematopoietic cells such as cancer cells, and SEMA6D expression was significantly negatively correlated with CD8A , PDCD1 , IFNG , and GZMB expression. Thus, targeting Sema6D forward signaling is a promising option for increasing ICI efficacy.


  • Open Access

    Tumor-derived semaphorin 4A improves PD-1–blocking antibody efficacy by enhancing CD8 + T cell cytotoxicity and proliferation

    by Yujiro Naito, Shohei Koyama, Kentaro Masuhiro, Takashi Hirai, Takeshi Uenami, Takako Inoue, Akio Osa, Hirotomo Machiyama, Go Watanabe, Nicolas Sax, et al.

    Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human Sema4A in the tumor microenvironment remains unclear. This study demonstrates that histologically Sema4A-positive non–small cell lung cancer (NSCLC) responded significantly better to anti–programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC. Intriguingly, SEMA4A expression in human NSCLC was mainly derived from tumor cells and was associated with T cell activation. Sema4A promoted cytotoxicity and proliferation of tumor-specific CD8 + T cells without terminal exhaustion by enhancing mammalian target of rapamycin complex 1 and polyamine synthesis, which led to improved efficacy of PD-1 inhibitors in murine models. Improved T cell activation by recombinant Sema4A was also confirmed using isolated tumor-infiltrating T cells from patients with cancer. Thus, Sema4A might be a promising therapeutic target and biomarker for predicting and promoting ICI efficacy.


  • Open Access

    Semaphorin 6D–expressing mesenchymal cells regulate IL-10 production by ILC2s in the lung

    by Maiko Naito, Yoshimitsu Nakanishi, Yasutaka Motomura, Hyota Takamatsu, Shohei Koyama, Masayuki Nishide, Yujiro Naito, Mayuko Izumi, Yumiko Mizuno, Yuta Yamaguchi, et al.

    Group 2 innate lymphoid cells (ILC2s) have been implicated in both physiologic tissue remodeling and allergic pathology, yet the niche signaling required for ILC2 properties is poorly understood. Here, we show that an axonal guidance cue semaphorin 6D (Sema6D) plays critical roles in the maintenance of IL-10–producing ILC2s.Sema6d−/−mice exhibit a severe steady-state reduction in ILC2s in peripheral sites such as the lung, visceral adipose tissue, and mesentery. Interestingly, loss of Sema6D results in suppressed alarmin-driven type 2 cytokine production but increased IL-10 production by lung ILC2s both in vitro and in vivo. Consequently,Sema6d−/−mice are resistant to the development of allergic lung inflammation. We further found that lung mesenchymal cells highly express Sema6D, and that niche-derived Sema6D is responsible for these phenotypes through plexin A1. Collectively, these findings suggest that niche-derived Sema6D is implicated in physiological and pathological characteristics of ILC2s.


  • Crosstalk between axon guidance signaling and bone remodeling

    by Yoshimitsu Nakanishi, Sujin Kang, Atsushi Kumanogoh


  • Open Access

    Neural guidance factors as hubs of immunometabolic cross-talk

    by Yoshimitsu Nakanishi, Sujin Kang, Atsushi Kumanogoh

    Semaphorins were originally identified as axon-guidance molecules essential for neural development. In addition to their functions in the neural system, members of the semaphorin family have critical functions in many pathophysiological processes, including immune responses, bone homeostasis, cancer and metabolic disorders. In particular, several lines of evidence indicate that mammalian/mechanistic target of rapamycin (mTOR), a central regulator of cell metabolism, regulates the functions of semaphorins in various types of cells, revealing a novel link between semaphorins and cell metabolism. In this review, we discuss recent advances in the immunometabolic functions of semaphorins, with a particular focus on mTOR signaling.


  • Open Access

    Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells

    by Yuhei Kinehara, Izumi Nagatomo, Shohei Koyama, Daisuke Ito, Satoshi Nojima, Ryota Kurebayashi, Yoshimitsu Nakanishi, Yasuhiko Suga, Yu Nishijima-Futami, Akio Osa, et al.

    Although responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) are initially positive, 30%–40% of patients with EGFR-mutant tumors do not respond well to EGFR-TKIs, and most lung cancer patients harboring EGFR mutations experience relapse with resistance. Therefore, it is necessary to identify not only the mechanisms underlying EGFR-TKI resistance, but also potentially novel therapeutic targets and/or predictive biomarkers for EGFR-mutant lung adenocarcinoma. We found that the GPI-anchored protein semaphorin 7A (SEMA7A) is highly induced by the EGFR pathway, via mTOR signaling, and that expression levels of SEMA7A in human lung adenocarcinoma specimens were correlated with mTOR activation. Investigations using cell culture and animal models demonstrated that loss or overexpression of SEMA7A made cells less or more resistant to EGFR-TKIs, respectively. The resistance was due to the inhibition of apoptosis by aberrant activation of ERK. The ERK signal was suppressed by knockdown of integrin β1 (ITGB1). Furthermore, in patients with EGFR mutant tumors, higher SEMA7A expression in clinical samples predicted poorer response to EGFR-TKI treatment. Collectively, these data show that the SEMA7A–ITGB1 axis plays pivotal roles in EGFR-TKI resistance mediated by ERK activation and apoptosis inhibition. Moreover, our results reveal the potential utility of SEMA7A not only as a predictive biomarker, but also as a potentially novel therapeutic target in EGFR-mutant lung adenocarcinoma.


  • Stepwise phosphorylation of leukotriene B4receptor 1 defines cellular responses to leukotriene B4

    by Yoshimitsu Nakanishi, Modong Tan, Takako Ichiki, Asuka Inoue, Jun-Ichi Yoshihara, Naoto Maekawa, Itsuki Takenoshita, Keisuke Yanagida, Shinya Yamahira, Satoshi Yamaguchi, et al.

    Sequential phosphorylation of the leukotriene B4receptor determines specific cellular responses to low and high concentrations of LTB4.


  • Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EB

    by Yoshitomo Hayama, Tetsuya Kimura, Yoshito Takeda, Shigeyuki Nada, Shohei Koyama, Hyota Takamatsu, Sujin Kang, Daisuke Ito, Yohei Maeda, Masayuki Nishide, et al.

    Amino acid metabolism plays important roles in innate immune cells, including macrophages. Recently, we reported that a lysosomal adaptor protein, Lamtor1, which serves as the scaffold for amino acid–activated mechanistic target of rapamycin complex 1 (mTORC1), is critical for the polarization of M2 macrophages. However, little is known about how Lamtor1 affects the inflammatory responses that are triggered by the stimuli for TLRs. In this article, we show that Lamtor1 controls innate immune responses by regulating the phosphorylation and nuclear translocation of transcription factor EB (TFEB), which has been known as the master regulator for lysosome and autophagosome biogenesis. Furthermore, we show that nuclear translocation of TFEB occurs in alveolar macrophages of myeloid-specific Lamtor1 conditional knockout mice and that these mice are hypersensitive to intratracheal administration of LPS and bleomycin. Our observation clarified that the amino acid–sensing pathway consisting of Lamtor1, mTORC1, and TFEB is involved in the regulation of innate immune responses.